Vera Therapeutics, Inc. (VERA)
|Net Income (ttm)||-53.41M|
|Trading Day||June 22|
|Day's Range||14.05 - 16.47|
|52-Week Range||11.30 - 26.97|
SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative trea...
Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The biotech will start trading on NAS...
SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments...
Vera Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Vera Therapeutics is a clinical stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. We are conducting a Phase 2b clinical trial of atac... [Read more...]
|IPO Date |
May 14, 2021
Marshall Fordyce, M.D.
|Stock Exchange |
|Ticker Symbol |